Clinical Trial

Long-Term Open-Label Extension Study of Oral Levosimendan

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-25; most recent amendment 2026-07-16.
Trial Details
NCT Number NCT07436689
Lead Sponsor Tenax Therapeutics, Inc.
Conditions Pulmonary Hypertension Associated With HFpEF
Enrollment 800 participants
Start Date 2026-03-13
Primary Completion 2029-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-20